Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion.
Yangzi LiQingya CuiSining LiuLingling LiuMegyn LiJun GaoZheng LiWei CuiXiaming ZhuLiqing KangLei YuDepei WuXiaowen TangPublished in: Cellular oncology (Dordrecht) (2024)
Rituximab combined with CAR-T therapy is effective for improving the long-term prognosis of B-ALL patients who have failed multiple lines of therapy. In vitro, we observed that rituximab potentially improves CAR-T efficacy by sensitizing ALL to CART-mediated cytotoxicity and reducing CAR-T exhaustion.
Keyphrases
- diffuse large b cell lymphoma
- end stage renal disease
- hodgkin lymphoma
- chronic lymphocytic leukemia
- newly diagnosed
- induced apoptosis
- chronic kidney disease
- ejection fraction
- acute myeloid leukemia
- bone marrow
- prognostic factors
- cell cycle arrest
- patient reported outcomes
- signaling pathway
- cell proliferation
- pi k akt